Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 11INDUSTRY 10NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Endocrine 2Thoracic 1NET 1CNS 1Breast 1

Conditions

Vipoma 2Somatostatinoma 2Insulinoma 2Glucagonoma 2Gastrinoma 2Carcinoma, Islet Cell 2Neuroendocrine Tumors 1Neoplasms 1Adenoma, Islet Cell 1

Interventions

Filgrastim 3Doxorubicin 3Temozolomide 2Octreotide 2Ifosfamide 2Etoposide 2Cisplatin 2Capecitabine 2vatalanib 1vandetanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1telotristat ethyl 1pegfilgrastim 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lanreotide 1batifiban 1Suramin 1Radiotherapy 1Platinum 1Mitotane 1Hydrocortisone 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Everolimus 1Ethane 1Docetaxel 1Dichlorodiphenyldichloroethane 1DNA Methylation 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Octreotide × Endocrine × Clear all
NCT00427349 2023-07-05

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Completed
46 enrolled 7 charts
EndocrineNET

Vipoma, Glucagonoma, Insulinoma, Adenoma, Islet Cell, Neoplasms, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell, Neuroendocrine Tumors

NCT00227773 2015-10-08

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Eastern Cooperative Oncology Group

Phase 2 Withdrawn
Endocrine

Vipoma, Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡